Moreover, dupilumab blocks both IL-4 and IL-13 signaling in treatment for patients with moderate to severe CRSwNP, thereby modulating downstream STAT6 or STAT3 phosphorylation via inactivation of JAK1 or JAK2; subsequently inflammation and tissue remodeling is able to be controlled and regulated [12]. Here, JAK1 is linked to chronic rhinosinusitis with nasal polyps.